KalVista Pharmaceuticals, Inc. (KALV)
Oxford Ledge is still expanding full research coverage of KALV. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
KalVista Pharmaceuticals develops oral therapies for rare diseases, with FDA approval of its lead product sebetralstat for treating hereditary angioedema attacks.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Entry into material agreement; Regulation FD disclosure; Financial statements and exhibits 2026-04-29
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-03-25
- 8-K Results of operations / financial condition; Regulation FD disclosure; Financial statements and exhibits 2026-01-08
- 10-Q Quarterly financial report (unaudited) 2025-11-10
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for KALV. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open KALV in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.